ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
61 992,11
1,81%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ARS Pharmaceuticals Inc (SPRY)

  7. ARS Pharmaceuticals Inc (SPRY) Actualités

SPRY

ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SPRY
DateHeureSourceTitreSymboleSociété
28/06/202412h30GlobeNewswire Inc.ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)NASDAQ:SPRYARS Pharmaceuticals Inc
18/06/202402h47Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SPRYARS Pharmaceuticals Inc
13/06/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
10/05/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
09/05/202422h05GlobeNewswire Inc.ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
30/04/202415h01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandNASDAQ:SPRYARS Pharmaceuticals Inc
03/04/202415h01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)NASDAQ:SPRYARS Pharmaceuticals Inc
21/03/202421h05GlobeNewswire Inc.ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
07/03/202422h05GlobeNewswire Inc.ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayNASDAQ:SPRYARS Pharmaceuticals Inc
06/03/202415h01GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:SPRYARS Pharmaceuticals Inc
26/02/202418h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
26/02/202415h01GlobeNewswire Inc.ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical studyNASDAQ:SPRYARS Pharmaceuticals Inc
22/02/202415h01GlobeNewswire Inc.ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024NASDAQ:SPRYARS Pharmaceuticals Inc
20/02/202415h01GlobeNewswire Inc.ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response LetterNASDAQ:SPRYARS Pharmaceuticals Inc
05/02/202415h01GlobeNewswire Inc.ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual MeetingNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202322h00GlobeNewswire Inc.ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
09/11/202317h02GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
06/10/202315h57Dow Jones NewsARS Pharmaceuticals to Meet With FDA on Neffy RejectionNASDAQ:SPRYARS Pharmaceuticals Inc
06/10/202315h03GlobeNewswire Inc.ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)NASDAQ:SPRYARS Pharmaceuticals Inc
03/10/202315h03GlobeNewswire Inc.Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical ImmunologyNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202316h20Dow Jones NewsARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy SetbackNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202312h30Dow Jones NewsARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy SprayNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202304h49GlobeNewswire Inc.FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional StudyNASDAQ:SPRYARS Pharmaceuticals Inc
10/08/202322h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPRYARS Pharmaceuticals Inc
10/08/202322h00GlobeNewswire Inc.ARS Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
28/06/202322h32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SPRYARS Pharmaceuticals Inc
20/06/202314h00GlobeNewswire Inc.ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
15/05/202315h08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SPRYARS Pharmaceuticals Inc
15/05/202315h00GlobeNewswire Inc.ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
12/05/202314h55Dow Jones NewsARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs NeffyNASDAQ:SPRYARS Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SPRY

Dernières Valeurs Consultées

NYSE
NKE
Nike
COIN
BTCUSD
Bitcoin
EU
AI
Air Liquide
NASDAQ
GOOGL
Alphabet
NYSE
MRK
Merck
NASDAQ
AMZN
Amazon.com
EU
CAP
Capgemini
NASDAQ
NVDA
NVIDIA
EU
RNO
Renault
EU
DG
Vinci
USI
USTECH100
US Tech 100
COIN
ETHUSD
Ethereum
EU
EN
Bouygues
NASDAQ
MSFT
Microsoft
EU
HO
Thales
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés